The Readout Loud
STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Episodes
Mentioned books
Dec 3, 2020 • 29min
Episode 139: Angela Rasmussen on AstraZeneca's confusing data, & Adam Koppel on biotech in 2021
Can too much Covid-19 vaccine be a bad thing? Is biotech in a bubble? And how do you make blind mice see again?
Nov 19, 2020 • 23min
Episode 138: The latest Covid-19 vaccine, Biden's pandemic plans, and Bill Gates unfiltered
How do we measure whether Covid-19 vaccines work? What does Joe Biden think of the drug industry? And does Anthony Fauci think about retirement?
Nov 12, 2020 • 29min
Episode 137: Natalie Dean on Pfizer's Covid-19 vaccine, plus the FDA's Alzheimer's quandary
How well does Pfizer's Covid-19 vaccine work? What's the difference between efficacy and effectiveness? And should the FDA approve Biogen's Alzheimer's drug?
Nov 5, 2020 • 27min
Bracing for a pandemic winter, Biogen's fortune at the FDA, and remembering a remarkable 12-year-old
How bad will this winter be? Is everything coming up Biogen? And who's going to be president on Jan. 20?
We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. First, STAT's Helen Branswell joins us to discuss what the winter has in store for the ongoing Covid-19 pandemic. Then, we discuss the latest surprising twist in Biogen’s quest to win FDA approval for a polarizing treatment for Alzheimer’s disease. Finally, STAT reporter Casey Ross joins to talk about the recent death and legacy of Bertrand Might, a 12-year boy born with a rare genetic disease.
Oct 29, 2020 • 30min
Episode 135: Pfizer's Covid-19 mystery, Ashish Jha on pandemic response, & STAT turns 5
When are we getting Covid-19 vaccine data? Will concerts ever be safe again? And what's a "Bionomy"?
Oct 22, 2020 • 25min
Episode 134: Erik Gordon on SPACs, plus Covid-19 vaccines, & Biogen's case in Alzheimer's
Who's voice rings loudest at the FDA? Is it wise to give hedge funds a blank check? And how will the Biogen saga end?
Oct 15, 2020 • 28min
Episode 133: A week of pauses, pharma’s statehouse spending, & how HBCUs approach Covid-19 trials
Is your local lawmaker flush with pharma cash? How does racism in medicine loom over Covid-19 studies? And who decides when a clinical trial goes on pause?
Oct 8, 2020 • 23min
Episode 132: How Trump's case of Covid-19 affects biotech, medicine, and the FDA with George Scangos
Why is the president making drug ads? Are antibodies the new vaccines? And is it ethical for doctors to talk about President Trump's health?
Oct 1, 2020 • 25min
Episode 131: Saad Omer on Covid-19 vaccine trials, & Ethan Weiss on intermittent fasting
Can an itchy arm ruin a clinical trial? Does intermittent fasting work? And is pharma more trustworthy than the CDC?
Sep 24, 2020 • 26min
Episode 130: A road map for Covid-19, the gold rush in health tech, & D.C.'s pandemic unrest
Is superspreading an Olympic event? Will Covid-19 forever change health tech? And what are the limits of Anthony Fauci's patience?
